ADRB2 and cancer: Because sustained stimulation of β2-AR in skeletal muscle supports anabolic and anti-catabolic processes, synthetic β2-AR agonists have been investigated as potential therapeutics to combat the loss of muscle mass and force-producing capacity associated with conditions such as neurogenic muscle atrophy9, 13, 14, muscular dystrophy15, 16, 17, sarcopenia6, 18, and cancer cachexia7, 19, 20.